Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Investigation Report on China Insulin Lispro Market, 2009-2018 - New Market Research Report


Print article Print article
2014-03-18 14:57:22 - New Pharmaceuticals research report from CRI is now available from Fast Market Research

Description
According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with 382 million patients worldwide. The number of diabetes patients in China was more than 98 million, ranking the first in the world. The rapid growth of diabetes patients is becoming a serious economic and social issue in China and other developing countries.

The first ultra-short-acting human insulin analogue insulin lispro (produced by Eli Lilly and Company with the trade name "Humalog") was launched in 1996 and approved by FDA. Insulin lispro is a fast acting insulin analogue with one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, allowing slightly more flexibility

than regular insulin, which requires a longer waiting period before starting a meal after injection. In 2012, global sales revenue of Humalog reached nearly USD 2.4 billion.

Full Report Details at
- www.fastmr.com/prod/782779_investigation_report_on_china_insulin ..

Humalog was launched in China in 2005 and its annual sales revenue continues to grow rapidly. According to CRI's investigation on certain Chinese sample hospital market, the sales revenue of insulin lispro in Chinese hospitals grew more than 100 times from 2005 to 2013. Most of the market is occupied by Eli Lilly and Company while the other belongs to Gan & Lee Pharmaceuticals. There used to be legal disputes between the two companies over the patent of insulin lispro in China. Based on CRI's investigation, insulin lispro produced by other Chinese enterprises will soon appear on the market.

Incidence of diabetes continues to rise in China as life improves and lifestyle changes. IDF predicts that the number of diabetes patients in China will reach 143 million in 2035, which is still top of the world. Since market size of insulin lispro is growing rapidly in China, huge potential exists in the market.

Through this report, the readers can acquire the following information:

* Incidence of Diabetes in China
* Market Share of Major Insulin Lispro Manufacturers in Sample Hospitals in China
* Sales Price of Insulin Lispro in Hospital Market in China

Patent Status of Insulin Lispro in China

* Production Status of Insulin Lispro in China
* Major Insulin Lispro Enterprises in China
* Prospect of China Insulin Lispro Market

The following enterprises and people are recommended to purchase this report:

* Anti-diabetic Drug Manufacturers
* Medical Institutions
* Investors /Research Agencies Focusing on Anti-diabetic Drug Market

Report Table of Contents:

Table of Contents
1 Relevant Concepts of Insulin Lispro
1.1 Indications and Development Process
1.2 Sales Status on the Global Market

2 Market Overview of Insulin Lispro in China
2.1 Launch Process
2.2 Patent Status
2.3 Patent Dispute between Eli Lilly and Company and Gan & Lee Pharmaceuticals
2.4 Market Size

3 Investigation on Sales Value of Insulin Lispro in China, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region

4 Investigation on Market Share of Major Insulin Lispro Manufacturers in China, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Investigation on Market Size of Insulin Lispro by Dosage Form in China, 2009-2013
5.1 Market Size by Sales Value
5.2 Market Size by Sales Volume

6 Reference Price of Insulin Lispro Produced by Different Enterprises in China Hospital Market, 2014
6.1 Lilly France
6.2 Gan & Lee Pharmaceuticals

7 Major Manufacturing Enterprises in China Insulin Lispro Market, 2009-2013
6.1 Eli Lilly and Company
6.2 Gan & Lee Pharmaceuticals

8 Prospect of China Insulin Lispro Market, 2014-2018
8.1 Prediction of Diabetes Incidence
8.2 Research Status of Generic Drug
8.3 Forecast on Market Size
8.4 Forecast on Market Competition

Selected Charts
Chart Sales Value of Humalog in Global Market, 2009-2013
Chart Insulin Lispro Products Approved to Market in China by 2014
Chart Sales Value of Insulin Lispro in China Sample Hospital Market, 2009-2013
Chart Sales Value of Insulin Lispro by Region in China, 2009-2013
Chart Market Share of Insulin Lispro Enterprises by Sales Value in China, 2009-2013
Chart Price of Insulin Lispro Produced by Lilly France in China Hospital Market, 2013
Chart Forecast on Market Size of Hospital-use Insulin Lispro in China, 2014-2018

About CRI

CRI is a research and consulting company located in Shanghai, China, focusing on various industries and markets. It regularly produces a variety of market research reports, industry analytical reports publications covering 11 industries. It also provides customized industry research services for initial public offerings, corporate mergers and acquisitions, business development, market launch and financing. View more research from CRI at www.fastmr.com/catalog/publishers.aspx?pubid=1045

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com